Histone deacetylase inhibitors (HDACis) target HDAC and inhibit its action, regulate the acetylation state of histones, and promote the transcription and expression of tumour transcription factors, and now has being developed as anti-tumour agents. Here, HDAC9 is linked to neoplasm.